No abstract

Ceria (CeO(2)) is a promising catalyst for the reduction of carbon dioxide (CO(2)) to liquid fuels and commodity chemicals, in part because of its high oxygen storage capacity, yet the fundamentals of CO(2) adsorption, activation, and reduction on ceria surfaces remain largely unknown. We use density functional theory, corrected for onsite Coulombic interactions (GGA+U), to explore various adsorption sites and configurations for CO(2) on stoichiometric and reduced ceria (110), the latter with either an in-plane oxygen vacancy or a split oxygen vacancy. We find that CO(2) adsorption on both reduced ceria (110) surfaces is thermodynamically favored over the corresponding adsorption on stoichiometric ceria (110), but the most stable adsorption configuration consists of CO(2) adsorbed parallel to the reduced ceria (110) surface at a split oxygen vacancy. Structural changes in the CO(2) molecule are also observed upon adsorption. At the split vacancy, the molecule bends out of plane to form a unidentate carbonate with the remaining oxygen anion at the surface; this is in stark contrast to the bridged carbonate observed for CO(2) adsorption at the in-plane vacancy. Also, we analyze the pathways for CO(2) conversion to CO on reduced ceria (110). The subtle difference in the energies of activation for the elementary steps suggest that CO(2) dissociation is favored on the split vacancy, while the reverse process of CO oxidation may favor the formation of the in-plane vacancy. We thus show how the structure and properties of the ceria catalyst govern the mechanism of CO(2) activation and reduction.

In aggregate, we delineate a paradigm of HLF/IL-6/STAT3 regulatory circuit in liver fibrosis and propose that HLF is a novel biomarker for activated HSCs and a potential target for antifibrotic therapy.

No abstract

Shp2 could promote HCC cell dedifferentiation and liver CSC expansion by amplifying β-catenin signaling and may be useful in predicting patient response to chemotherapeutics. (Hepatology 2017;65:1566-1580).

Chemical looping methane partial oxidation provides an energy and cost effective route for methane utilization. However, there is considerable CO2 co-production in current chemical looping systems, rendering a decreased productivity in value-added fuels or chemicals. In this work, we demonstrate that the co-production of CO2 can be dramatically suppressed in methane partial oxidation reactions using iron oxide nanoparticles embedded in mesoporous silica matrix. We experimentally obtain near 100% CO selectivity in a cyclic redox system at 750–935 °C, which is a significantly lower temperature range than in conventional oxygen carrier systems. Density functional theory calculations elucidate the origins for such selectivity and show that low-coordinated lattice oxygen atoms on the surface of nanoparticles significantly promote Fe–O bond cleavage and CO formation. We envision that embedded nanostructured oxygen carriers have the potential to serve as a general materials platform for redox reactions with nanomaterials at high temperatures.

Our results not only clarify the cellular and molecular mechanisms underlying the inflammation-mediated LCSC generation but also provide a molecular classification for the individualized treatment of liver cancer. (Hepatology 2017;66:1934-1951).

Background and aimsThe unique expression pattern makes oncofetal proteins ideal diagnostic biomarkers and therapeutic targets in cancer. However, few oncofetal proteins have been identified and entered clinical practice.MethodsFetal liver, adult liver and hepatocellular carcinoma (HCC) tissues were employed to assess the expression of hepatic leukaemia factor (HLF). The impact of HLF on HCC onset and progression was investigated both in vivo and in vitro. The association between HLF and patient prognosis was determined in patient cohorts. The correlation between HLF expression and sorafenib benefits in HCC was further evaluated in patient cohorts and patient-derived xenografts (PDXs).ResultsHLF is a novel oncofetal protein which is reactivated in HCC by SOX2 and OCT4. Functional studies revealed that HLF transactivates c-Jun to promote tumour initiating cell (TIC) generation and enhances TIC-like properties of hepatoma cells, thus driving HCC initiation and progression. Consistently, our clinical investigations elucidated the association between HLF and patient prognosis and unravelled the close correlation between HLF levels and c-Jun expression in patient HCCs. Importantly, HLF/c-Jun axis determines the responses of hepatoma cells to sorafenib treatment, and interference of HLF abrogated c-Jun activation and enhanced sorafenib response. Analysis of patient cohorts and PDXs further suggests that HLF/c-Jun axis might serve as a biomarker for sorafenib benefits in HCC patients.ConclusionsOur findings uncovered HLF as a novel oncofetal protein and revealed the crucial role of the HLF/c-Jun axis in HCC development and sorafenib response, rendering HLF as an optimal target for the prevention and intervention of HCC.